MedPath

Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial)

Not Applicable
Recruiting
Conditions
Stroke
Ischemic Stroke
Carotid Artery Diseases
Carotid Artery Stenosis
Interventions
Device: Carotid Wallstent
Device: Timing Carotid Stent
Registration Number
NCT05574972
Lead Sponsor
Suzhou Zenith Vascular Scitech Co., Ltd.
Brief Summary

Evaluate the safety and efficacy of the Timing Carotid Stent for the treatment of carotid artery stenosis in patients.

Detailed Description

This is a prospective, randomized, concurrent controlled, multi-center study. Patients with carotid artery stenosis will be assigned to either the Timing Carotid Stent or Carotid Wallstent. Each treated patient will be followed and assessed for 12 months after randomization. The hypothesis to be tested is that the safety and effectiveness of the Timing Carotid Stent is not inferior to the Carotid Wallstent.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
178
Inclusion Criteria
  1. Aged 18-85 years;
  2. Patient is either symptomatic with carotid stenosis ≥50% OR asymptomatic with carotid stenosis ≥70% ;
  3. Target lesion 3.5- 5.5 mm;
  4. Signed informed consent.
Exclusion Criteria
  1. Target lesion is not caused by atherosclerotic disease;
  2. Target lesion is located at the opening of the common carotid artery;
  3. Patient has severe lesion calcification that may restrict the full deployment of the carotid
  4. Patient has a total occlusion of the target carotid arteries
  5. Patient has a large number of acute or subacute thrombi and arteriovenous malformations near the target lesion
  6. Patient has a severe stenosis or occlusion in series with target lesions
  7. Patient has known severe carotid stenosis contralateral to the target lesion
  8. Patient need angioplasty in other parts (including intracranial and extracranial) at the same time or within 30 days after procedure
  9. Patient has a symptomatic severe stenosis of other blood vessels (including intracranial and extracranial) except carotid artery
  10. Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke or intracranial hemorrhage
  11. Patient has a massive stroke or myocardial infarction
  12. Patient has a intracranial aneurysm
  13. Patient has a coagulation dysfunction or abnormal bleeding, or contraindications to heparin and antiplatelet drugs
  14. Patient has known sensitivity to contrast agent
  15. Patient has a platelet < 90 × 109 / L, severe liver and kidney injury, and severe dysfunction of important organs such as heart, lung, liver and kidney
  16. Patient has a uncontrollable severe hyperemia
  17. Patient has a bradycardia
  18. mRS≥3
  19. Patient has life expectancy of less than one year
  20. Patient is currently enrolled in another investigational study protocol
  21. Females who are pregnant or in lactation
  22. Other conditions not suitable for inclusion judged by the researcher -

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Carotid WallstentCarotid Wallstent-
Timing Carotid StentTiming Carotid Stent-
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Experienced Major Adverse Events (MAE) at 30 days30 days

MAE defined as any death, stroke, or myocardial infarction through 30 days post-index procedure

Secondary Outcome Measures
NameTimeMethod
Number of Participants Who Achieved Stent Technical SuccessProcedural

Stent Technical Success defined as successful implantation of a Carotid Stent

Number of Participants Who Achieved Procedure SuccessProcedural

Number of Participants Who Achieved Procedure Success

Ipsilateral ischemic stroke1 year

Any ipsilateral ischemic stroke through 1 year post-index procedure

In-Stent Restenosis1 year

≥50% diameter stenosis within the stented lesion or within 5 mm proximal or distal to the stent at follow-up evaluation

mRS score change1 year

mRS score change through 1 year post-index procedure

Target Lesion Revascularization30 days

Any clinically driven revascularization procedure that is performed to increase the luminal diameter inside or within 5 mm of the previously treated lesion

Trial Locations

Locations (1)

Xuanwu Hospital

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath